22 September 2017 - NICE has issued a final positive recommendation for Bayer’s Eylea as a treatment for adults for the treatment of visual impairment due to myopic chorodial neovascularisation.

Myopic CNV is a common vision-threatening complication of myopia and pathological myopia (severe near-sightedness).

Pathologic myopia affects up to three percent of the population, of which myopic CNV occurs in approximately five-10 percent of patients. The long term prognosis is poor, with 90 percent of patients reaching the threshold for ‘legal blindness’ within five years of diagnosis.

Read Pharma Times article